Silence Therapeutics
SLN
55 hedge funds and large institutions have $108M invested in Silence Therapeutics in 2025 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 12 increasing their positions, 19 reducing their positions, and 13 closing their positions.
1,786% more call options, than puts
Call options by funds: $132K | Put options by funds: $7K
78% more capital invested
Capital invested by funds: $60.6M → $108M (+$47.4M)
50.55% more ownership
Funds ownership: 15.47% → 66.02% (+51%)
7% less funds holding
Funds holding: 59 → 55 (-4)
31% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 13
37% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$3.75M |
| 2 |
SL
Siren LLC
Greenwich,
Connecticut
|
+$521K |
| 3 |
Jane Street
New York
|
+$162K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$119K |
| 5 |
WC
Wexford Capital
West Palm Beach,
Florida
|
+$116K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$3.38M |
| 2 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
-$2.99M |
| 3 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$1.13M |
| 4 |
Millennium Management
New York
|
-$850K |
| 5 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$765K |
SLN Hedge Fund Activity: Q2 2025 in Review
55 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Silence Therapeutics (SLN) for Q2 2025, worth a combined $108M — up 78% from $60.6M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of SLN and 9 opened new positions — a net loss of 4 holders — while 19 trimmed existing stakes and 12 added.
The largest buyer was Ikarian Capital, opening a new position worth an estimated $3.75M. The largest seller was Morgan Stanley, cutting an estimated $3.38M.
- 55 institutional investors held Silence Therapeutics (SLN) as of Q2 2025, down from 59 in Q1 2025.
- Funds reported $108M of Silence Therapeutics stock for Q2 2025, up 78% quarter-over-quarter.
- 9 funds opened new Silence Therapeutics positions in Q2 2025 and 13 closed out, a net change of -4 holders.
- The largest Silence Therapeutics buyer in Q2 2025 was Ikarian Capital, an estimated $3.75M added.
- The largest Silence Therapeutics seller in Q2 2025 was Morgan Stanley, an estimated $3.38M sold.
Based on aggregated 13F filings for Q2 2025.